pretickt

VCYT financials

Veracyte, Inc. · end-of-day data as of Nov 13, 2026

Veracyte
VCYT · $1.96B
$24.33-1.2%
Nov 13, 2026 · close
$40SepOctNov9:3016:003 months -40.2%Nov 13 · close
▲ 7
  • PT$54.14 +122.5%
  • ConsensusBuy · 14
  • P/E vs own-58.8%
  • P/E vs sector-51.0%
  • FCF yield+8.2%
  • RSI28
  • Sector▲ +15.9%
Neutral
  • Earnings in103d
  • P/E15.8x
  • Support-4.4%
  • Resistance+8.5%
  • Off 52w high-60.1%
  • Volume0.8x
  • Bollingerlower half
  • News0.00
  • Trendsideways
  • 52w range$22–$61
  • ATR+14.5%
  • Off ATH-71.7%
▼ 4
  • Insiders-$2.86M
  • MAs0 of 4
  • MA20×50Death 3d ago
  • MACD-2.50

Updates with the 15-min delayed price. Not a forecast or investment advice.

Veracyte VCYT reported revenue of $152M for the quarter ended Sep 30, 2026 (Q3 FY2026), up 15.1% from a year earlier. It posted diluted EPS of $0.38, free cash flow of $37.92M and a net margin of 20.8%.

Valuation

  • P/E15.8x
  • P/E vs own-58.8%
  • P/E vs sector-51.0%
  • FCF yield+8.2%
  • Market cap$1.96B

Quarterly results

Q3 FY2026: Revenue +15.1% year over year, free cash flow 25.0% of revenue, operating margin 10.9%.

RevenueFree cash flow
Q4 FY2023Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Q3 FY2026Sep 30, 2026$152M0.38$37.92M70.6%10.9%20.8%
Q2 FY2026Jun 30, 2026$150M0.31$42.97M72.2%15.3%17.0%
Q1 FY2026Mar 31, 2026$139M0.35$32.25M72.3%17.1%20.6%
Q4 FY2025Dec 31, 2025$141M0.50$48.27M74.4%18.4%29.3%
Q3 FY2025Sep 30, 2025$132M0.24$41.97M69.2%17.4%14.5%
Q2 FY2025Jun 30, 2025$130M-0.01$32.32M69.0%-4.0%-0.8%
Q1 FY2025Mar 31, 2025$114M0.09$3.54M69.5%2.5%6.2%
Q4 FY2024Dec 31, 2024$119M0.06$20.38M66.4%3.5%4.3%
Q3 FY2024Sep 30, 2024$116M0.19$27.72M68.2%10.4%13.1%
Q2 FY2024Jun 30, 2024$114M0.07$26.8M68.1%4.0%5.0%
Q1 FY2024Mar 31, 2024$96.84M-0.02-$11.1M64.5%-4.8%-1.9%
Q4 FY2023Dec 31, 2023$98.2M-0.39$13.05M70.1%-36.2%-28.8%